Effects of Combination of Proliferative Agents and Erythropoietin on Left Ventricular Remodeling Post-Myocardial Infarction

Rosemeire Takeuchi, Lauro M. Takeuchi, Konstantinos Hatzistergos, Henry Quevedo, Sarah M. Selem, Adriana V. Treuer, Courtney Premer, Wayne E Balkan, Irene Margitich, Yun Song, Qinghua Hu, Joshua Hare

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post-myocardial infarction (MI) effects synergistically. Methods: After MI, five to seven animals were randomly assigned to each of the following treatments: control; hCG; EPO; hCG + EPO, and prolactin (PRL) + EPO. Follow-up echocardiograms were performed to assess cardiac structure and function. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and western blot analysis for apoptosis-related proteins, and cell proliferation by immunostaining for Ki67 and c-kit cells. Results: The MI-mediated increased chamber systolic dimension (p < 0.05 in controls) was attenuated by hCG, EPO, and hCG + EPO (p < 0.05 vs. control) but not PRL + EPO. Similarly all treatment groups, except PRL + EPO, reduced MI-induced increases (p < 0.05 vs. control) in ejection fraction (EF). The functional improvement in the EPO-treated groups was accompanied by increased capillary density. Apoptosis was markedly reduced in all treated groups. Significantly more cardiac c-kit+ cells were found in the hCG + EPO group. Conclusion: Our findings revealed that EPO, hCG, or their combination ameliorate cardiac remodeling post-MI. Whereas EPO stimulates neovascularization only and hCG + EPO stimulates c-kit+ cell proliferation. These data suggest that combining mobilizing and proliferative agents adds to the durability and sustainability of cytokine-based therapies for remodeling post-MI.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalClinical and Translational Science
Volume4
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Ventricular Remodeling
Erythropoietin
Myocardial Infarction
Chorionic Gonadotropin
Prolactin
Cell proliferation
Apoptosis
Cell Proliferation
DNA Nucleotidylexotransferase
Endothelial cells
Labeling
Sustainable development

Keywords

  • Cytokines
  • Erythropoietin
  • Heart failure
  • Myocardial infarction
  • Remodeling

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effects of Combination of Proliferative Agents and Erythropoietin on Left Ventricular Remodeling Post-Myocardial Infarction. / Takeuchi, Rosemeire; Takeuchi, Lauro M.; Hatzistergos, Konstantinos; Quevedo, Henry; Selem, Sarah M.; Treuer, Adriana V.; Premer, Courtney; Balkan, Wayne E; Margitich, Irene; Song, Yun; Hu, Qinghua; Hare, Joshua.

In: Clinical and Translational Science, Vol. 4, No. 3, 01.06.2011, p. 168-174.

Research output: Contribution to journalArticle

Takeuchi, Rosemeire ; Takeuchi, Lauro M. ; Hatzistergos, Konstantinos ; Quevedo, Henry ; Selem, Sarah M. ; Treuer, Adriana V. ; Premer, Courtney ; Balkan, Wayne E ; Margitich, Irene ; Song, Yun ; Hu, Qinghua ; Hare, Joshua. / Effects of Combination of Proliferative Agents and Erythropoietin on Left Ventricular Remodeling Post-Myocardial Infarction. In: Clinical and Translational Science. 2011 ; Vol. 4, No. 3. pp. 168-174.
@article{898ea0f4d0c0455cbe4b819c6b92bace,
title = "Effects of Combination of Proliferative Agents and Erythropoietin on Left Ventricular Remodeling Post-Myocardial Infarction",
abstract = "Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post-myocardial infarction (MI) effects synergistically. Methods: After MI, five to seven animals were randomly assigned to each of the following treatments: control; hCG; EPO; hCG + EPO, and prolactin (PRL) + EPO. Follow-up echocardiograms were performed to assess cardiac structure and function. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and western blot analysis for apoptosis-related proteins, and cell proliferation by immunostaining for Ki67 and c-kit cells. Results: The MI-mediated increased chamber systolic dimension (p < 0.05 in controls) was attenuated by hCG, EPO, and hCG + EPO (p < 0.05 vs. control) but not PRL + EPO. Similarly all treatment groups, except PRL + EPO, reduced MI-induced increases (p < 0.05 vs. control) in ejection fraction (EF). The functional improvement in the EPO-treated groups was accompanied by increased capillary density. Apoptosis was markedly reduced in all treated groups. Significantly more cardiac c-kit+ cells were found in the hCG + EPO group. Conclusion: Our findings revealed that EPO, hCG, or their combination ameliorate cardiac remodeling post-MI. Whereas EPO stimulates neovascularization only and hCG + EPO stimulates c-kit+ cell proliferation. These data suggest that combining mobilizing and proliferative agents adds to the durability and sustainability of cytokine-based therapies for remodeling post-MI.",
keywords = "Cytokines, Erythropoietin, Heart failure, Myocardial infarction, Remodeling",
author = "Rosemeire Takeuchi and Takeuchi, {Lauro M.} and Konstantinos Hatzistergos and Henry Quevedo and Selem, {Sarah M.} and Treuer, {Adriana V.} and Courtney Premer and Balkan, {Wayne E} and Irene Margitich and Yun Song and Qinghua Hu and Joshua Hare",
year = "2011",
month = "6",
day = "1",
doi = "10.1111/j.1752-8062.2011.00278.x",
language = "English",
volume = "4",
pages = "168--174",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of Combination of Proliferative Agents and Erythropoietin on Left Ventricular Remodeling Post-Myocardial Infarction

AU - Takeuchi, Rosemeire

AU - Takeuchi, Lauro M.

AU - Hatzistergos, Konstantinos

AU - Quevedo, Henry

AU - Selem, Sarah M.

AU - Treuer, Adriana V.

AU - Premer, Courtney

AU - Balkan, Wayne E

AU - Margitich, Irene

AU - Song, Yun

AU - Hu, Qinghua

AU - Hare, Joshua

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post-myocardial infarction (MI) effects synergistically. Methods: After MI, five to seven animals were randomly assigned to each of the following treatments: control; hCG; EPO; hCG + EPO, and prolactin (PRL) + EPO. Follow-up echocardiograms were performed to assess cardiac structure and function. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and western blot analysis for apoptosis-related proteins, and cell proliferation by immunostaining for Ki67 and c-kit cells. Results: The MI-mediated increased chamber systolic dimension (p < 0.05 in controls) was attenuated by hCG, EPO, and hCG + EPO (p < 0.05 vs. control) but not PRL + EPO. Similarly all treatment groups, except PRL + EPO, reduced MI-induced increases (p < 0.05 vs. control) in ejection fraction (EF). The functional improvement in the EPO-treated groups was accompanied by increased capillary density. Apoptosis was markedly reduced in all treated groups. Significantly more cardiac c-kit+ cells were found in the hCG + EPO group. Conclusion: Our findings revealed that EPO, hCG, or their combination ameliorate cardiac remodeling post-MI. Whereas EPO stimulates neovascularization only and hCG + EPO stimulates c-kit+ cell proliferation. These data suggest that combining mobilizing and proliferative agents adds to the durability and sustainability of cytokine-based therapies for remodeling post-MI.

AB - Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post-myocardial infarction (MI) effects synergistically. Methods: After MI, five to seven animals were randomly assigned to each of the following treatments: control; hCG; EPO; hCG + EPO, and prolactin (PRL) + EPO. Follow-up echocardiograms were performed to assess cardiac structure and function. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and western blot analysis for apoptosis-related proteins, and cell proliferation by immunostaining for Ki67 and c-kit cells. Results: The MI-mediated increased chamber systolic dimension (p < 0.05 in controls) was attenuated by hCG, EPO, and hCG + EPO (p < 0.05 vs. control) but not PRL + EPO. Similarly all treatment groups, except PRL + EPO, reduced MI-induced increases (p < 0.05 vs. control) in ejection fraction (EF). The functional improvement in the EPO-treated groups was accompanied by increased capillary density. Apoptosis was markedly reduced in all treated groups. Significantly more cardiac c-kit+ cells were found in the hCG + EPO group. Conclusion: Our findings revealed that EPO, hCG, or their combination ameliorate cardiac remodeling post-MI. Whereas EPO stimulates neovascularization only and hCG + EPO stimulates c-kit+ cell proliferation. These data suggest that combining mobilizing and proliferative agents adds to the durability and sustainability of cytokine-based therapies for remodeling post-MI.

KW - Cytokines

KW - Erythropoietin

KW - Heart failure

KW - Myocardial infarction

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=79959763069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959763069&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2011.00278.x

DO - 10.1111/j.1752-8062.2011.00278.x

M3 - Article

C2 - 21707946

AN - SCOPUS:79959763069

VL - 4

SP - 168

EP - 174

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 3

ER -